



Mouse Anti-Bevacizumab monoclonal antibody, clone BZ21 (CABT-L0361Y)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies. No cross reaction with Human $lgG1\kappa$, Human $lgG1\lambda$, Herceptin, or Adalimumab. Recommended for PK/PD assays
Specificity	Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies. No cross reaction with Human $lgG1\kappa$, Human $lgG1\lambda$,Herceptin, or Adalimumab.
Immunogen	Bevacizumab F(ab)2
Isotype	IgG1
Source/Host	Mouse
Species Reactivity	N/A
Clone	BZ21
Conjugate	Unconjugated
Applications	Suitable for PK bridging ELISA We recommend the following for sandwich ELISA (Capture - Detection): CABT-L0361Y - CABT-L0362Y. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Preparation	Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab)2.
Format	Purified, Lyophilized

45-1 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882 Fax: 1-631-938-8221

Email: info@creative-diagnostics.com

© Creative Diagnostics All Rights Reserved

Size	100 ug
Buffer	Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Preservative	None
Storage	This product is stable -70°C for 12 months under sterile conditions after reconstitution.

BACKGROUND

Introduction	Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons
Keywords	VEGF; Bevacizumab